Starfire Investment Advisers Inc. bought a new position in shares of Bristol-Myers Squibb Co (NYSE:BMY) in the fourth quarter, HoldingsChannel.com reports. The firm bought 4,278 shares of the biopharmaceutical company’s stock, valued at approximately $262,000.

A number of other large investors have also modified their holdings of BMY. Vanguard Group Inc. lifted its holdings in shares of Bristol-Myers Squibb by 0.3% in the second quarter. Vanguard Group Inc. now owns 118,661,690 shares of the biopharmaceutical company’s stock worth $6,611,829,000 after buying an additional 333,685 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Bristol-Myers Squibb by 2.4% in the second quarter. BlackRock Inc. now owns 99,454,602 shares of the biopharmaceutical company’s stock worth $5,541,612,000 after buying an additional 2,367,864 shares in the last quarter. Dodge & Cox lifted its holdings in shares of Bristol-Myers Squibb by 1.6% in the second quarter. Dodge & Cox now owns 29,579,461 shares of the biopharmaceutical company’s stock worth $1,648,168,000 after buying an additional 459,271 shares in the last quarter. Jennison Associates LLC lifted its holdings in shares of Bristol-Myers Squibb by 16.2% in the third quarter. Jennison Associates LLC now owns 26,854,242 shares of the biopharmaceutical company’s stock worth $1,711,689,000 after buying an additional 3,735,453 shares in the last quarter. Finally, Northern Trust Corp lifted its holdings in shares of Bristol-Myers Squibb by 3.9% in the second quarter. Northern Trust Corp now owns 24,041,862 shares of the biopharmaceutical company’s stock worth $1,339,612,000 after buying an additional 910,496 shares in the last quarter. Hedge funds and other institutional investors own 69.56% of the company’s stock.

Bristol-Myers Squibb Co (BMY) opened at $63.87 on Wednesday. Bristol-Myers Squibb Co has a 52-week low of $51.56 and a 52-week high of $66.10. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. The company has a market cap of $103,373.98, a P/E ratio of 108.25, a price-to-earnings-growth ratio of 1.96 and a beta of 1.09.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of $0.67 by $0.01. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 33.68%. The business had revenue of $5.45 billion for the quarter, compared to analysts’ expectations of $5.35 billion. During the same period last year, the business earned $0.63 earnings per share. The business’s quarterly revenue was up 3.9% on a year-over-year basis. equities research analysts predict that Bristol-Myers Squibb Co will post 3.22 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, February 1st. Shareholders of record on Friday, January 5th were given a dividend of $0.40 per share. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 dividend on an annualized basis and a yield of 2.51%. The ex-dividend date was Thursday, January 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 271.19%.

In other news, EVP Thomas J. Jr. Lynch sold 5,300 shares of the firm’s stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total value of $335,172.00. Following the transaction, the executive vice president now owns 9,251 shares in the company, valued at $585,033.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Sandra Leung sold 156,582 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the completion of the transaction, the executive vice president now owns 584,373 shares in the company, valued at approximately $37,031,717.01. The disclosure for this sale can be found here. 0.23% of the stock is owned by company insiders.

A number of equities research analysts recently weighed in on the stock. Vetr downgraded shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $60.72 target price on the stock. in a research note on Thursday, February 8th. BMO Capital Markets lowered their target price on shares of Bristol-Myers Squibb from $52.00 to $51.00 and set an “underperform” rating on the stock in a research note on Tuesday, February 6th. Leerink Swann raised their target price on shares of Bristol-Myers Squibb from $71.00 to $76.00 and gave the company a “positive” rating in a research note on Tuesday, February 6th. Zacks Investment Research downgraded shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research note on Monday, January 29th. Finally, Credit Suisse Group set a $62.00 target price on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Monday, January 22nd. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $65.58.

COPYRIGHT VIOLATION WARNING: “4,278 Shares in Bristol-Myers Squibb Co (BMY) Purchased by Starfire Investment Advisers Inc.” was originally posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://theolympiareport.com/2018/02/14/4278-shares-in-bristol-myers-squibb-co-bmy-purchased-by-starfire-investment-advisers-inc.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.